Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 290,392
  • Shares Outstanding, K 58,665
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,290 K
  • 60-Month Beta 1.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.14
  • Prior Year -0.14
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.60 +29.17%
on 06/11/20
5.66 -17.84%
on 06/23/20
+0.75 (+19.23%)
since 06/05/20
3-Month
2.74 +69.71%
on 04/07/20
5.66 -17.84%
on 06/23/20
+1.70 (+57.63%)
since 04/06/20
52-Week
2.20 +111.36%
on 03/16/20
6.31 -26.31%
on 02/19/20
+1.18 (+34.01%)
since 07/05/19

Most Recent Stories

More News
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX(R)3-71 (AF710B)

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 4.65 (-6.06%)
Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX(R)2-73 (Blarcamesine) in Patients with Rett Syndrome

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 4.65 (-6.06%)
Here's Why Anavex Life Sciences (AVXL) is a Great Momentum Stock to Buy

Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.

AVXL : 4.65 (-6.06%)
Thinking about buying stock in Microvision, InVitae Corp, Alpine Immune Sciences, Anavex Life Sciences, or Ford Motor?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVIS, NVTA, ALPN, AVXL, and F.

ALPN : 9.50 (-6.68%)
AVXL : 4.65 (-6.06%)
F : 6.19 (+2.31%)
NVTA : 32.49 (+2.43%)
NASDAQ Higher for Fifth Straight Day as Stocks Rally in Final Hour

NASDAQ Higher for Fifth Straight Day as Stocks Rally in Final Hour

SPOT : 260.26 (-4.14%)
TDOC : 218.00 (+4.36%)
UNFI : 18.54 (+1.98%)
ZS : 114.78 (+4.15%)
ACMR : 80.84 (+22.69%)
ESTC : 93.54 (-1.10%)
CRUS : 62.01 (+2.24%)
EVOP : 21.75 (-2.90%)
CMC : 20.11 (+1.41%)
SCHN : 17.14 (+1.72%)
CVET : 18.39 (+2.82%)
XOM : 44.39 (+0.70%)
UNG : 10.71 (+6.25%)
WEAT : 5.05 (+0.20%)
FVRR : 78.35 (+2.42%)
SPTN : 20.88 (-0.10%)
DSPG : 15.89 (+1.60%)
ALNY : 152.43 (+1.71%)
AVXL : 4.65 (-6.06%)
EDIT : 30.68 (+0.49%)
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?

Is (AVXL) Outperforming Other Medical Stocks This Year?

AVXL : 4.65 (-6.06%)
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX(R)2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 4.65 (-6.06%)
Anavex Life Sciences (AVXL) Moves to Buy: Rationale Behind the Upgrade

Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AVXL : 4.65 (-6.06%)
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX(R)2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer's Disease

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental...

AVXL : 4.65 (-6.06%)
Has Anavex Life Sciences (AVXL) Outpaced Other Medical Stocks This Year?

Is (AVXL) Outperforming Other Medical Stocks This Year?

AVXL : 4.65 (-6.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AVXL with:

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

2nd Resistance Point 5.24
1st Resistance Point 4.94
Last Price 4.65
1st Support Level 4.39
2nd Support Level 4.14

See More

52-Week High 6.31
Fibonacci 61.8% 4.74
Last Price 4.65
Fibonacci 50% 4.26
Fibonacci 38.2% 3.77
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar